Both in Biotechnology
Denali Therapeutics vs Beam Therapeutics
Over the past year DNLI returned +38.3% and BEAM returned +14.0%; their daily moves had a correlation of 0.47.
DNLI +38.3% BEAM +14.0%Growth of $1, one year, split-adjusted
| Metric | DNLI | BEAM |
|---|---|---|
| Price | $19.45 | $26.33 |
| Market cap | $3.11B | $2.72B |
| Today | +3.13% | +1.78% |
| 1 month | −2.3% | +2.6% |
| 6 months | +2.8% | −8.9% |
| Year to date | +17.8% | −5.0% |
| 1 year | +19.5% | +5.3% |
| Revenue growth (YoY) | — | −94.2% |
| Gross margin | 97.4% | 100.0% |
| Net margin | −3539.2% | −25036.3% |
| P/E (TTM) | — | — |
| Price / sales | 862.7× | 17.4× |
| Net cash | $705.0M | $1.05B |
| Dividend yield | — | — |
| Volatility (60d) | 38.0% | 63.4% |
| Short % of float | 11.6% | 32.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).